[1] Shoaei SD, Sali S, Karamipour M, et al. Non-invasive histologic markers of liver disease in patients with chronic hepatitis B. Hepat Mon, 2014, 14: e14228. [2] Zeng X, Xu C, He D, et al. Performance of several simple, noninvasive models for assessing significant liver fibrosis in patients with chronic hepatitis B. Croat Med J, 2015, 56: 272-279. [3] Wan R, Liu H, Wang X, et al. Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B. Int J Clin Exp Med, 2015, 8: 961-971. [4] Cheng J, Hou J, Ding H, et al. Validation of ten noninvasive diagnostic models for prediction of liver fibrosis in patients with chronic hepatitis B. PLoS ONE, 2015, 10: e0144425. [5] Motola DL, Caravan P, Chung RT, et al. Noninvasive biomarkers of liver fibrosis: clinical applications and future directions. Curr Pathobiol Rep, 2014, 2: 245-256. [6] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015更新版). 肝脏,2015,20: 915-932. [7] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 2016, 10: 1-98. [8] European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical practice guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol, 2015, 63: 237-264. [9] World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: WHO Press, 2015: 25-35. [10] 张占卿,陆伟,王雁冰,等. 血清HBsAg和HBV DNA对慢性乙型肝炎肝组织病理状态的判别评价. 中华临床医师杂志(电子版), 2013, 7: 6841-6847. [11] 张占卿, 陆伟, 王雁冰, 等. 年龄和血清 HBsAg、HBV DNA预测慢性乙型肝炎肝组织病理状态的研究. 同济大学学报(医学版), 2015, 36: 50-57. [12] 张占卿,陆伟,王雁冰,等.血清HBsAg和HBV DNA预测慢性乙型肝炎肝组织病理状态的评价.胃肠病学和肝病学杂志,2013, 23: 5541-559. [13] 张占卿, 陆伟,翁齐铖, 等. 血清病毒学标记物预测慢性乙型肝炎肝组织病理状态的评价. 同济大学学报(医学版), 2015, 36: 57-63. [14] 张占卿, 陆伟,翁齐铖, 等. 血清乙型肝炎核心相关抗原预测慢性乙型肝炎肝组织病理状态的评价. 肝脏, 2015, 20: 576-582. [15] Zeng DW, Zhang JM, Liu YR, et al. A retrospective study on the significance of liver biopsy and hepatitis B surface antigen in chronic hepatitis B infection. Medicine, 2016, 95: e2503. [16] Jia W, Qi X, Ji YY, et al. Low serum hepatitis B surface antigen level predicts compensated cirrhosis caused by chronic hepatitis B in HBeAg positive patients in east China. Hepat Mon, 2015, 15:e29183. [17] Alam S, Ahmad N, Mustafa G, et al. Evaluation of normal or minimally elevated alanine transaminase, age and DNA level in predicting liver histological changes in chronic hepatitis B. Liver Int, 2011, 31:824-830. [18] Croagh CMN, Bell SJ, Slavin J, et al. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int, 2010, 30: 1115 -1122. [19] Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond. Hepatology, 2000, 31: 241-246. [20] Xun YH, Zang GQ, Guo JH, et al. Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers. J Gastroeterol Hepatol, 2013, 28: 1746-1755. [21] Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naive, e antigen-positive patients. J Hepatol, 2013, 58: 1089-1095. [22] Seto WK, Wong DKH, Fung J, et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS One, 2012, 7: e43087. [23] Cheng PN, Tsai HW, Chiu YC, et al. Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B. J Clin Virol, 2013, 57: 323-330. [24] Alam S, Ahmad N, Mustafa G, et al. Evaluation of normal or minimally elevated alanine transaminase, age and DNA level in predicting liver histological changes in chronic hepatitis B. Liver Int, 2011, 31: 824-830. [25] McMahon BJ, Bulkow L, Simons B, et al. Relationship between level of HBV DNA and liver disease-a population-based study of hepatitits B e antigen-negative persons with hepatitis B. Clin Gastroenterol Hepatol, 2014, 12: 701-706. [26] Praneenararat S, Chamroonkul N, Sripongpun P, et al. HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication. BMC Gastroenterology, 2014, 14: 218. [27] Croagh CMN, Bell SJ, Slavin J, et al. Increasing hepatitis B viral load is associated with risk of signi? cant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int, 2010, 30: 1115-1122. [28] Sanai FM, Helmy A, Bzeizi KI, et al. Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B. J Viral Hepat, 2011, 18: e217- e225. |